Aardvark Therapeutics, Inc. Aardvark Therapeutics, Inc. is listed today as Aardvark Therapeutics, Inc. : market value, financials and filings are on its company page.
Funding rounds 3 counted as startup funding. Open the number of investors for the round's details.
Funding rounds of Aardvark Therapeutics, Inc. Month Raised Raise Size Investors Sold Filing May 2024 $85 M No. 3 $50 to $250 million 31
Aardvark Therapeutics, Inc.: Raise no. 3, May 2024 × Investors in this round 31 investors had bought by the notice of May 15, 2024: 31 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $85 M of $85 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,699,999
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Nelson Sun · Executive Officer Tien-Li Lee · Executive Officer, Director Jeffrey Chi · Director Victor Tong · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Cantor Fitzgerald & Co. (CRD 134) · New York, New York Sold in CA, CO, CT, FL, MA, NY, TX Signed by Tien-Li Lee, Ceo. Newest notice filed May 15, 2024. Read the notice at the SEC .
equity SEC May 2021 $9 M No. 2 $2 to $10 million 8
Aardvark Therapeutics, Inc.: Raise no. 2, May 2021 × Investors in this round 8 investors had bought by the notice of Jun 7, 2021: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $9 M of $30 M offered; $21 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Tien-Li Lee · Executive Officer, Director Bob Shin · Director Henry Ji · Director Jeffrey Chi · Director Jerel Banks · Director Zachary Hornby · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tien-Li Lee, Ceo. Newest notice filed Jun 7, 2021. Read the notice at the SEC .
equity SEC May 2019 $9 M No. 1 $2 to $10 million 12
Aardvark Therapeutics, Inc.: Raise no. 1, May 2019 × Investors in this round 12 investors had bought by the notice of May 24, 2019: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $9 M of $15 M offered; $6 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Tien-Li Lee · Executive Officer, Director Bob Shin · Director Jeffrey Chi · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tien-Li Lee, Chief Executive Officer. Newest notice filed May 24, 2019. Read the notice at the SEC .
equity SEC
What its filings and its own website say, sentence by sentence, each with its source.
Aardvark Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (May 2024).
SEC Form D · May 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · May 2024
No products or services of Aardvark Therapeutics, Inc. are on record.
No investor of Aardvark Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Largest shareholders today Institutions holding Aardvark Therapeutics, Inc. shares, as of Sep 30, 2026.
As of Sep 30, 2026
Executives and directors As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by Aardvark Therapeutics, Inc. Name Role Named in Nelson Sun Executive officer May 2024 Tien-Li Lee Executive officer May 2024 Jeffrey Chi Director May 2024 Tien-Li Lee Director May 2024 Victor Tong Director May 2024 Bob Shin Director Jun 2021 Henry Ji Director Jun 2021 Jerel Banks Director Jun 2021 Zachary Hornby Director Jun 2021
Went public since 2025. Its SEC number is that of a company listed on a stock exchange.